A two-year, multicenter, double-blind, randomized, placebo-controlled and parallel group study of oral risedronate 5 mg daily in the prevention of osteoporosis in osteopenic postmenopausal women (more than 5 years postmenopausal)

Trial Profile

A two-year, multicenter, double-blind, randomized, placebo-controlled and parallel group study of oral risedronate 5 mg daily in the prevention of osteoporosis in osteopenic postmenopausal women (more than 5 years postmenopausal)

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2009

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jul 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
    • 19 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top